Latest Health And Wellness News

Nutritional Growth Solutions has completed a $760,000 share placement at a slight discount, aiming to boost inventory and support its retail growth strategy.

Decidr AI Industries reported an 82% revenue jump in its AI platform during Q4 FY25, launched AI Mentors with The Growth Faculty, and divested its 13Seeds business to sharpen focus on AI innovation.

Jatcorp Limited reported a robust 76% revenue increase in Q4 FY25, driven by strong Moroka® sales and expanded manufacturing capabilities, setting ambitious growth targets for FY26.

Holista Colltech reported steady customer receipts and a 38% surge in dietary supplement sales for 2QFY25, while progressing its high-value nano-collagen business and refreshing its leadership team.

EZZ Life Science Holdings marked a pivotal quarter with the launch of its EZZDAY brand in the US, a significant Southeast Asia distribution agreement, and expanded domestic retail presence, driving a 46% jump in customer receipts.

Global Health Limited reported a robust June quarter with a 65% rise in annual sales and a strategic pivot towards AI-driven efficiencies, aiming for profitability by mid-2026.

Biome Australia Limited has reported a 69% increase in international sales revenue for FY25, reaching $1.5 million, driven by new strategic distribution agreements across Ireland, New Zealand, and Canada.

Artrya Limited has secured a five-year, US$0.6 million contract with Tanner Health, marking its inaugural commercial revenue in the U.S. market for its AI-powered Salix Coronary Anatomy platform.

Holista Colltech has confirmed Leong Man Loong as its permanent CEO, cementing leadership stability during a pivotal recovery phase. His symbolic $1 salary underscores a commitment to long-term growth.

Thrive Tribe Technologies has announced a proposed 20, 1 share consolidation aimed at streamlining its capital structure, pending shareholder approval at the upcoming Extraordinary General Meeting.

EZZ Life Science has inked a three-year distribution deal with ROFA Enterprises, marking a significant step into Southeast Asia’s booming health market. The agreement guarantees at least A$21 million in sales across Thailand, Vietnam, and Singapore.

EVE Health Group has initiated stability testing for its novel oral treatments targeting erectile dysfunction and dysmenorrhea, marking a crucial step toward regulatory approval in Australia. The company also finalizes its acquisition of Nextract, the developer behind these innovative formulations.